DeCure's autonomous Psychiatry AI scientist is researching a drug-repurposing hypothesis for macrocephaly-autism syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMacrocephaly-autism syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for macrocephaly-autism syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphatase and tensin homolog (PTEN) — PTEN is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet +drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1D5R · 2.1 Å · ligand L(+)-TARTARIC ACID (TLA). Experimental structure, not a prediction.
What the evidence adds up to
No pharmacological treatment has shown a consistent effect on the core social disability of autism. The 2007 review states that drugs targeted to possible neurochemical systems can reduce aggression, self-injury, and interfering repetitive behaviour, but no pharmacotherapeutic has yet shown a primary effect on core social impairment. The 2008 review similarly notes that despite the absence of a pharmacological cure, some dysfunctional behaviours may be treated pharmacologically. The 2019 narrative review is more direct: there is no cure for autism spectrum disorder, and sufficient evidence does not exist to support most claimed pharmacological and dietary therapies. Proven benefits were observed only with applied behavioural analysis and some psychopharmacologic agents, but the review does not name which agents.
The 2023 overview of stem-cell therapy for ASD reports that the preponderance of research suggests stem-cell therapy improves aspects of outcome measure scales, but it is based on a small set of published trials. The authors do not claim efficacy or a reliable cure, and they propose additional steps if the field is to be pursued further. The 2014 paper on treatment response measurement notes that measuring treatment response is difficult due to the heterogeneity of symptom changes, which can be subtle, especially over short periods. It calls for continued development of outcome measures to help identify and compare efficacious interventions.
What is still missing is a consistent, replicated finding from adequately powered randomised controlled trials for any drug or cellular therapy in macrocephaly-autism syndrome specifically. The existing evidence is drawn from heterogeneous autism spectrum populations, not from this defined genetic subgroup. No trial has stratified patients by underlying genetic cause, and no funding stream is dedicated to repurposing candidates for this particular syndrome. Without such stratification and dedicated trials, claims of efficacy remain unsupported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Harvard Review of Psychiatry · 2008 · 78 citations
Pharmacological Treatment Options for Autism Spectrum Disorders in Children and Adolescents
AbstractAutism and other pervasive developmental disorders (PDDs) are frequently associated with dysfunctional behaviors and are characterized by deficits in socialization, communication, and behavioral rigidity. Despite the absence of a pharmacological cure for PDDs, many of the dysfunctional, coinciding behaviors may be treated pharmacologically. This article reviews what is known about the efficacy and tolerability of pharmacological interventions for the treatment of children and adolescents suffering from autistic spectrum disorders.
Where is the Evidence? A Narrative Literature Review of the Treatment Modalities for Autism Spectrum Disorders
AbstractThe most important thing about autism spectrum disorder (ASD) is that there is, in fact, no cure for this disorder; however, currently, there are many claims of pharmacological and dietary therapies and behavioral interventions that are said to improve outcome or even lead to "cure" or "recovery." It continues to remain a challenging condition for children and their families. Research conducted on many of these treatment modalities is limited and, consequently, sufficient evidence does not exist to support their use. The primary aim of this paper was to search for the evidence of the efficacy of each treatment for autism till now. We reviewed different treatment modalities and randomized clinical trials on each treatment to look for the evidence. Although there are interventions that may be effective in alleviating some symptoms and improving skills that help autistic persons lead more productive lives, proven benefits were observed only with applied behavioral analysis (ABA) and some psychopharmacologic agents.
Regenerative Medicine · 2023 · 2 citations · open access
The Promise of Autologous and Allogeneic Cellular Therapies in the Clinical Trials of Autism Spectrum Disorder
AbstractAutism spectrum disorder (ASD) is a consortium of developmental conditions. As scientists have not yet identified the exact underlying cause for these disorders, it is not easy to narrow down a singular therapy to propose a reliable cure. The preponderance of research suggests that stem-cell therapy improves aspects of outcome measure scales in patients with ASD; therefore, future studies should give us more confidence in the results. This overview considers the data that have emerged from the small set of published trials conducted using different approaches in stem-cell therapy for ASD, evaluates their results and proposes additional steps that could be taken if this field of endeavor is to be pursued further.
Cambridge University Press eBooks · 2007 · 2 citations
Psychopharmacology
AbstractResearch into the pharmacotherapy of individuals with pervasive developmental disorders (PDDs) has increased steadily over the last 20 years, and more rapidly over the last several years, as treatment successes have triggered more rigorous study. The use of drugs targeted to possible neurochemical systems involved in the pathophysiology of autistic disorder (autism) have been shown to often reduce aggression, self-injury, and interfering repetitive behavior in these patients (Cook, 1990). No pharmacotherapeutics have yet shown a consistent primary effect on the core social disability of autism. Combined with comprehensive individualized treatment programs, appropriate pharmacotherapy can enhance an autistic person's ability to benefit from educational and behavior modification techniques (McDougle et al., 1994). This chapter will comprehensively highlight significant research in the psychopharmacology of PDDs from the perspective of specific neurochemical systems.
Situation of the Uninsured in Khon Kaen Municipal area, 2005(สภาพขอเทจจรงทเกยวของกบผไมมสทธหลกประกนสขภาพ ในเขตเทศบาลนครขอนแกน ป 2548)
AbstractSignificant advancements have been made in early intervention programs for children with Autism spectrum disorder (ASD). However, measuring treatment response for children with ASD is difficult due to the heterogeneity of changes in symptoms, which can be subtle, especially over a short period of time. Here we outline the challenge of evaluating treatment response with currently available measures as well as newly developed or refined measures that may be useful in clinical trials for young children with ASD. Continued development of treatment outcome measures will help the field identify and compare efficacious interventions and tailor treatments for children with ASD.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
